glp-1 drugs pharmaceutical companies partnerships 2025 Receptor Agonist Market Size and Share GLP-1 Market Size, Share |

In the current study, the researchers analyzed 3,081,254 patients with diabetes and 929,174 patients without diabetes, adjusting for patient sex, age and history of depression and anxiety

Still, that has not stopped some doctors from prescribing these medications "off-label" for weight loss, which means they are used for a different purpose than explicitly intended

Retatrutide: A triple incretin receptor agonist for obesity management

15, eadh4453 (2023)

Source: Polaris Market Research Analysis To Understand More About this Research:Download Sample Report Why GLP-1 Matters

Keywords Information Type Review Copyright The Author(s), 2024